Osk reprogramming

2 papers6 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: European Molecular Biology Organization and 3 more
3 of 6 findings with company ties

Animals2

Outcomes

Cellular senescence

downin mice2

2 studies

Osk reprogramming decreases cellular senescence in mice.
“reversed the expression of senescence- and disease-related cellular hallmarks in aged mice and models of Alzheimer's disease (AD)”
Animalsin aged mice and models of Alzheimer's diseaseengram neurons
Cognitive rejuvenation through partial reprogramming of engram cells
Neuron10 Feb 2026
Osk reprogramming decreases cellular senescence in mice.
“reduced expression of genes involved in the inflammation, senescence and stress response pathways”
Animalslong-term
In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice
Nature aging7 Mar 2022